Cleveland HeartLab (CHL) has raised $18.4 million through a round of series B funding. The round was led by Excel Venture Management and HealthCare Ventures, while existing investors also took part.
The funds will support CHL’s continued rapid growth and assist in market adoption of its advanced approach to evaluating cardiovascular disease risk using biomarkers of inflammation. CHL is a specialty clinical laboratory and disease management company.
Click here for the release from Cleveland HeartLab.